Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches

Davodabadi, Fatemeh; Sarhadi, Mohammad; Arabpour, Javad; Sargazi, Saman; Rahdar, Abbas; Díez‐Pascual, Ana M.

doi:10.1016/j.jconrel.2022.07.036

Cited by 25 publications

(25 citation statements)

References 402 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, NeuVax, a peptide vaccine against breast cancer, completed phase III clinical trial and declared safety in vivo ( 3 ). This is the furthest step in the quest for epitope vaccines for use in humans to date ( 4 , 5 ), suggesting the effectiveness of strategies and the bright application prospect to design peptide-based vaccines ( 6 , 7 ).…”

Section: Introductionmentioning

confidence: 99%

Integration: Gospel for immune bioinformatician on epitope-based therapy

Sun

Zhang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Integration: Gospel for immune bioinformatician on epitope-based therapy

Sun

Zhang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

“…However, much evidence has described immunogenic activity in the BC subtypes [ 35 , 36 ]. This finding is allowing a variety of studies to explore the great potential of different immunotherapies in BC patients [ 37 ] to provide predictive and prognostic information, and to optimize standard therapies (surgery, RT, CT, and ET), which has resulted in improved clinical outcomes with a significant improvement in survival rates [ 38 ]. However, increasing BC immunogenicity and modulating the TME are some necessary strategies for improving therapeutic efficacy.…”

Section: Immunotherapy In Breast Cancermentioning

confidence: 99%

“…In other types of BC vaccines, telomerase is involved. This ribonucleoprotein has polymerase activity to maintain telomere length and leads to cellular immortalization, so its aberrant expression is associated with increased survival and proliferation of tumor cells [ 38 , 64 ]. It is overexpressed in most tumors, including BC [ 38 , 39 , 65 ].…”

Section: Immunotherapy In Breast Cancermentioning

confidence: 99%

“…This ribonucleoprotein has polymerase activity to maintain telomere length and leads to cellular immortalization, so its aberrant expression is associated with increased survival and proliferation of tumor cells [ 38 , 64 ]. It is overexpressed in most tumors, including BC [ 38 , 39 , 65 ]. The synthetic hTERT DNA vaccine, INO-1400, is composed of a plasmid encoding for the catalytic subunit of hTERT with two immunogenic differentiating mutations that elicit a broad CTL-mediated immune response against tumor cells.…”

Section: Immunotherapy In Breast Cancermentioning

confidence: 99%

“…Yan and colleagues demonstrated the potent immunity exerted by this vaccine in preclinical murine and primate models [ 37 ]. In mice, hTERT generated a strong immune response characterized by the increase of CD107a-, interferon (IFN)ɣ-, and tumor necrosis factor (TNF)α-producing cells [ 38 , 66 ]. In monkeys, slower tumor growth and longer overall survival (OS) were achieved, and minimal side effects upon administration were observed [ 66 ].…”

Section: Immunotherapy In Breast Cancermentioning

confidence: 99%

See 2 more Smart Citations

Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells

Sánchez-León

Jiménez‐Cortegana

Romeiro

et al. 2023

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) continues to be the most diagnosed tumor in women and a very heterogeneous disease both inter- and intratumoral, mainly given by the variety of molecular profiles with different biological and clinical characteristics. Despite the advancements in early detection and therapeutic strategies, the survival rate is low in patients who develop metastatic disease. Therefore, it is mandatory to explore new approaches to achieve better responses. In this regard, immunotherapy arose as a promising alternative to conventional treatments due to its ability to modulate the immune system, which may play a dual role in this disease since the relationship between the immune system and BC cells depends on several factors: the tumor histology and size, as well as the involvement of lymph nodes, immune cells, and molecules that are part of the tumor microenvironment. Particularly, myeloid-derived suppressor cell (MDSC) expansion is one of the major immunosuppressive mechanisms used by breast tumors since it has been associated with worse clinical stage, metastatic burden, and poor efficacy of immunotherapies. This review focuses on the new immunotherapies in BC in the last five years. Additionally, the role of MDSC as a therapeutic target in breast cancer will be described.

show abstract

Nanotechnology‐Based Strategies for Extended‐Release Delivery of Angiotensin Receptor Blockers (ARBs): A Comprehensive Review

Haji Ali,

Shirvaliloo,

Fathi‐Karkan

et al. 2023

Chemistry & Biodiversity

Self Cite

View full text Add to dashboard Cite

There has been a significant shift in the perception of hypertension as an important contributor to the global disease burden. Approximately 6% and 8% of pregnancies are affected by hypertension, which can adversely affect the mother and the fetus. Furthermore, a hypertensive individual is at increased risk of developing kidney disease, arterial hardening, eye damage, and strokes. Using angiotensin receptor blockers (ARBs) is widespread in treating hypertension, heart failure, coronary artery disease, and diabetic nephropathy. Despite this, some ARBs have limited use due to their poor oral bioavailability and water solubility. To tackle this, a variety of nanoparticle (NP)‐based systems, such as polymeric NPs (i.e., dendrimers), polymeric micelles, polymer‐drug conjugates, lipid NPs, nanoemulsions, self‐emulsifying drug delivery systems (SEDDS), solid lipid NPs (SLNs), nanostructured lipid carriers (NLCs), carbon‐based nanocarriers, inorganic NPs, and nanocrystals, have been recently developed for efficient delivery of losartan, Valsartan (Val), Olmesartan (OLM), Telmisartan (TEL), Candesartan, Eprosartan, Irbesartan, and Azilsartan to target cells. This review article provides a literature‐based comparison of the various classes of ARBs, their mechanisms of action, and an overview of the nanoformulations developed for ARB delivery and successfully applied to managing hypertension, diabetic complications, and other conditions.

show abstract

Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches

Cited by 25 publications

References 402 publications

Integration: Gospel for immune bioinformatician on epitope-based therapy

Integration: Gospel for immune bioinformatician on epitope-based therapy

Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells

Nanotechnology‐Based Strategies for Extended‐Release Delivery of Angiotensin Receptor Blockers (ARBs): A Comprehensive Review

Contact Info

Product

Resources

About